Sex steroid and growth factor profile of a meningioma associated with pregnancy

Justin S. Smith, Alfredo Quinones-Hinojosa, Miranda Harmon-Smith, Andrew W. Bollen, Michael W. McDermott

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Increased growth of meningiomas during pregnancy as well as postpartum clinical regression of symptoms have been reported but remain poorly understood. A better understanding of the factors that contribute to these observations, including potential factors associated with pregnancy, could enable design of more effective adjuvant therapies. Methods: We describe the presentation of a meningioma during the immediate postpartum period. Serial imaging demonstrated subsequent rapid decrease in size of the tumour prior to any intervention. The lesion was resected, and the tissue was subjected to immunostaining for gene products associated with pregnancy, including estrogen receptor (ER), progesterone receptor (PR), platelet-derived growth factor receptor B (PDGFRB), fibroblastic growth factor receptor 2 (FGFR-2), epidermal growth factor receptor (EGFR) and human placental lactogen (hPL). Results: The lesion proved to be an atypical fibroblastic meningioma grade II (WHO). Immunostaining demonstrated significant staining for PR, PDGFRB, and FGFR-2. No specific staining for ER, EGFR, or hPL was identified. Conclusion: Although clinical regression of meningioma following pregnancy is well-recognized, imaging data are much less abundant. This report provides clear clinical and imaging documentation of a meningioma associated with pregnancy. In addition, the growth factor profile of this tumour suggests the importance of PR, PDGFRB, and FGFR-2 as potential therapeutic targets.

Original languageEnglish (US)
Pages (from-to)122-127
Number of pages6
JournalCanadian Journal of Neurological Sciences
Volume32
Issue number1
StatePublished - Feb 2005
Externally publishedYes

Fingerprint

Sex Factors
Meningioma
Proto-Oncogene Proteins c-sis
Intercellular Signaling Peptides and Proteins
Platelet-Derived Growth Factor Receptors
Steroids
Growth Factor Receptors
Progesterone Receptors
Pregnancy
Placental Lactogen
Epidermal Growth Factor Receptor
Estrogen Receptors
Postpartum Period
Staining and Labeling
Documentation
Neoplasms
Therapeutics
Growth
Genes

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Sex steroid and growth factor profile of a meningioma associated with pregnancy. / Smith, Justin S.; Quinones-Hinojosa, Alfredo; Harmon-Smith, Miranda; Bollen, Andrew W.; McDermott, Michael W.

In: Canadian Journal of Neurological Sciences, Vol. 32, No. 1, 02.2005, p. 122-127.

Research output: Contribution to journalArticle

Smith, JS, Quinones-Hinojosa, A, Harmon-Smith, M, Bollen, AW & McDermott, MW 2005, 'Sex steroid and growth factor profile of a meningioma associated with pregnancy', Canadian Journal of Neurological Sciences, vol. 32, no. 1, pp. 122-127.
Smith, Justin S. ; Quinones-Hinojosa, Alfredo ; Harmon-Smith, Miranda ; Bollen, Andrew W. ; McDermott, Michael W. / Sex steroid and growth factor profile of a meningioma associated with pregnancy. In: Canadian Journal of Neurological Sciences. 2005 ; Vol. 32, No. 1. pp. 122-127.
@article{e1f0acacdb45451da18d69785e24838e,
title = "Sex steroid and growth factor profile of a meningioma associated with pregnancy",
abstract = "Background: Increased growth of meningiomas during pregnancy as well as postpartum clinical regression of symptoms have been reported but remain poorly understood. A better understanding of the factors that contribute to these observations, including potential factors associated with pregnancy, could enable design of more effective adjuvant therapies. Methods: We describe the presentation of a meningioma during the immediate postpartum period. Serial imaging demonstrated subsequent rapid decrease in size of the tumour prior to any intervention. The lesion was resected, and the tissue was subjected to immunostaining for gene products associated with pregnancy, including estrogen receptor (ER), progesterone receptor (PR), platelet-derived growth factor receptor B (PDGFRB), fibroblastic growth factor receptor 2 (FGFR-2), epidermal growth factor receptor (EGFR) and human placental lactogen (hPL). Results: The lesion proved to be an atypical fibroblastic meningioma grade II (WHO). Immunostaining demonstrated significant staining for PR, PDGFRB, and FGFR-2. No specific staining for ER, EGFR, or hPL was identified. Conclusion: Although clinical regression of meningioma following pregnancy is well-recognized, imaging data are much less abundant. This report provides clear clinical and imaging documentation of a meningioma associated with pregnancy. In addition, the growth factor profile of this tumour suggests the importance of PR, PDGFRB, and FGFR-2 as potential therapeutic targets.",
author = "Smith, {Justin S.} and Alfredo Quinones-Hinojosa and Miranda Harmon-Smith and Bollen, {Andrew W.} and McDermott, {Michael W.}",
year = "2005",
month = "2",
language = "English (US)",
volume = "32",
pages = "122--127",
journal = "Canadian Journal of Neurological Sciences",
issn = "0317-1671",
publisher = "Canadian Journal of Neurological Sciences",
number = "1",

}

TY - JOUR

T1 - Sex steroid and growth factor profile of a meningioma associated with pregnancy

AU - Smith, Justin S.

AU - Quinones-Hinojosa, Alfredo

AU - Harmon-Smith, Miranda

AU - Bollen, Andrew W.

AU - McDermott, Michael W.

PY - 2005/2

Y1 - 2005/2

N2 - Background: Increased growth of meningiomas during pregnancy as well as postpartum clinical regression of symptoms have been reported but remain poorly understood. A better understanding of the factors that contribute to these observations, including potential factors associated with pregnancy, could enable design of more effective adjuvant therapies. Methods: We describe the presentation of a meningioma during the immediate postpartum period. Serial imaging demonstrated subsequent rapid decrease in size of the tumour prior to any intervention. The lesion was resected, and the tissue was subjected to immunostaining for gene products associated with pregnancy, including estrogen receptor (ER), progesterone receptor (PR), platelet-derived growth factor receptor B (PDGFRB), fibroblastic growth factor receptor 2 (FGFR-2), epidermal growth factor receptor (EGFR) and human placental lactogen (hPL). Results: The lesion proved to be an atypical fibroblastic meningioma grade II (WHO). Immunostaining demonstrated significant staining for PR, PDGFRB, and FGFR-2. No specific staining for ER, EGFR, or hPL was identified. Conclusion: Although clinical regression of meningioma following pregnancy is well-recognized, imaging data are much less abundant. This report provides clear clinical and imaging documentation of a meningioma associated with pregnancy. In addition, the growth factor profile of this tumour suggests the importance of PR, PDGFRB, and FGFR-2 as potential therapeutic targets.

AB - Background: Increased growth of meningiomas during pregnancy as well as postpartum clinical regression of symptoms have been reported but remain poorly understood. A better understanding of the factors that contribute to these observations, including potential factors associated with pregnancy, could enable design of more effective adjuvant therapies. Methods: We describe the presentation of a meningioma during the immediate postpartum period. Serial imaging demonstrated subsequent rapid decrease in size of the tumour prior to any intervention. The lesion was resected, and the tissue was subjected to immunostaining for gene products associated with pregnancy, including estrogen receptor (ER), progesterone receptor (PR), platelet-derived growth factor receptor B (PDGFRB), fibroblastic growth factor receptor 2 (FGFR-2), epidermal growth factor receptor (EGFR) and human placental lactogen (hPL). Results: The lesion proved to be an atypical fibroblastic meningioma grade II (WHO). Immunostaining demonstrated significant staining for PR, PDGFRB, and FGFR-2. No specific staining for ER, EGFR, or hPL was identified. Conclusion: Although clinical regression of meningioma following pregnancy is well-recognized, imaging data are much less abundant. This report provides clear clinical and imaging documentation of a meningioma associated with pregnancy. In addition, the growth factor profile of this tumour suggests the importance of PR, PDGFRB, and FGFR-2 as potential therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=14944362700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944362700&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 122

EP - 127

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

SN - 0317-1671

IS - 1

ER -